RxDoctor Payments Data

Cole Milliken, MD

Ophthalmology · Charleston, SCNPI 1477110799

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (55.7%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Alcon at 53.7% of the total. 2025 is the largest year on record at $12,707, more than ten times the $329 reported in 2020. Among ophthalmology clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,710in general payments, 2019–2025

Across 112 payments — averaging $149.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$9K
  • Tarsus Pharmaceuticals, Inc.$2K
  • Glaukos Corporation$1K
  • Biotissue Holdings Inc.$868
  • AbbVie$819
  • Alcon Research LLC$650
  • plus $3K from 14 others

What the payments were for

  • Consulting fees$9,30056%
  • Speaking & faculty fees$3252%
  • Food & beverage$6,79441%
  • Education$2912%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,710 in reported general payments places this provider in the 90th percentile of 293 ophthalmology providers in South Carolina.

See all ophthalmology providers in South Carolina

Medicare billing

Part B allowed, 2024
$69,367
Medicare patients
270
Services billed
601

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine20$19,102
Prednisolone Acetate102$4,118
Fluorometholone24$1,683
ValacyclovirValacyclovir Hcl16$1,021
MoxifloxacinMoxifloxacin Hcl48$1,014
Latanoprost43$505
ErythromycinErythromycin Base20$316
Doxycycline Hyclate18$291
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat22$289
Timolol Maleate26$164
Brimonidine Tartrate11$125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$819$19,10220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 293 ophthalmology providers in South Carolina.

Other ophthalmology in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →